Browse STX17

Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein Smooth endoplasmic reticulum membrane Multi-pass membrane protein Endoplasmic reticulum-Golgi intermediate compartment membrane Multi-pass membrane protein Cytoplasmic vesicle, autophagosome membrane Multi-pass membrane protein Cytoplasmic vesicle, COPII-coated vesicle membrane Multi-pass membrane protein Cytoplasm, cytosol Note=Has a hairpin-like insertion into membranes. Localizes to the completed autophagosome membrane upon cell starvation (PubMed:23217709). May also localize to the mitochondria according to PubMed:23217709.
Domain -
Function

SNAREs, soluble N-ethylmaleimide-sensitive factor-attachment protein receptors, are essential proteins for fusion of cellular membranes. SNAREs localized on opposing membranes assemble to form a trans-SNARE complex, an extended, parallel four alpha-helical bundle that drives membrane fusion. STX17 is a SNARE of the autophagosome involved in autophagy through the direct control of autophagosome membrane fusion with the lysosome membrane (PubMed:23217709, PubMed:25686604). May also play a role in the early secretory pathway where it may maintain the architecture of the endoplasmic reticulum-Golgi intermediate compartment/ERGIC and Golgi and/or regulate transport between the endoplasmic reticulum, the ERGIC and the Golgi (PubMed:21545355).

> Gene Ontology
 
Biological Process GO:0000045 autophagosome assembly
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006906 vesicle fusion
GO:0006914 autophagy
GO:0007030 Golgi organization
GO:0007033 vacuole organization
GO:0016050 vesicle organization
GO:0016236 macroautophagy
GO:0022406 membrane docking
GO:0034497 protein localization to pre-autophagosomal structure
GO:0044801 single-organism membrane fusion
GO:0048193 Golgi vesicle transport
GO:0048278 vesicle docking
GO:0048284 organelle fusion
GO:0061025 membrane fusion
GO:0090174 organelle membrane fusion
GO:0097111 endoplasmic reticulum-Golgi intermediate compartment organization
GO:0097352 autophagosome maturation
GO:0097576 vacuole fusion
GO:1905037 autophagosome organization
Molecular Function GO:0000149 SNARE binding
GO:0005484 SNAP receptor activity
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
Cellular Component GO:0000421 autophagosome membrane
GO:0005776 autophagosome
GO:0005790 smooth endoplasmic reticulum
GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0012507 ER to Golgi transport vesicle membrane
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030868 smooth endoplasmic reticulum membrane
GO:0030897 HOPS complex
GO:0031201 SNARE complex
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
GO:0044232 organelle membrane contact site
GO:0044233 ER-mitochondrion membrane contact site
GO:0097425 smooth endoplasmic reticulum part
GO:0099023 tethring complex
> KEGG and Reactome Pathway
 
KEGG hsa04130 SNARE interactions in vesicular transport
hsa04140 Regulation of autophagy
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STX17 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STX17 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STX17 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.150.486
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0640.952
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.210.805
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0230.938
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3130.844
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3450.866
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0320.921
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1740.908
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1210.942
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1530.872
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.620.626
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0340.513
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STX17 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STX17. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STX17. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STX17.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STX17. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STX17 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STX17 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTX17
Namesyntaxin 17
Aliases FLJ20651; Syntaxin-17
Chromosomal Location9q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STX17 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.